Table 3.
Management of all patients, patients with and without an abnormal RVEF, and patients with and without LGE
| All patients (n = 290) | Abnorma l RVEF (n = 35) | Normal RVEF (n = 255) | p value | RV LGE (n = 16) | No RV LGE (n = 274) | p value | |
|---|---|---|---|---|---|---|---|
| Endomyocardial biopsy performed, n (%) | 22 (7.6) | 10 (28.6) | 12 (4.7) | <0.001 | 9 (56.3) | 13 (4.7) | <0.001 |
| Steroids for any sarcoidosis indication, n (%) | 153 (52.8) | 26 (74.3) | 127 (49.8) | <0.001 | 10 (62.5) | 143 (52.2) | 0.43 |
| Non-steroidal immune modulatory agents for any sarcoidosis indication, n (%) | 114 (39.3) | 18 (51.4) | 96 (37.6) | 0.12 | 9 (56.3) | 105 (38.3) | 0.15 |
| Steroids for suspected cardiac sarcoidosis, n (%) | 53 (18.3) | 15 (42.9) | 38 (14.9) | <0.001 | 10 (62.5) | 43 (15.7) | <0.001 |
| Non-steroidal immune modulatory agents for suspected cardiac sarcoidosis, n (%) | 39 (13.4) | 10 (28.6) | 29 (11.4) | 0.005 | 9 (56.3) | 30 (10.9) | <0.001 |
| Pacemaker-only implantation, n (%) | 9 (3.1) | 2 (5.7) | 7 (2.7) | 0.34 | 3 (18.8) | 6 (2.2) | <0.001 |
| ICD implantation, n (%) | 37 (12.8) | 12 (34.3) | 25 (9.8) | <0.001 | 14 (87.5) | 23 (8.4) | <0.001 |
| Left ventricular assist device placement, n (%) | 2 (0.7) | 1 (2.9) | 1 (0.4) | 0.10 | 1 (6.3) | 1 (0.4) | 0.006 |
| Orthotopic heart transplantation, n (%) | 3 (1.0) | 2 (5.7) | 1 (0.4) | 0.004 | 2 (12.5) | 1 (0.4) | <0.001 |
Values are n (%). EF = ejection fraction; ICD = implantable cardioverter-defibrillator; LGE = late gadolinium enhancement; LV = left ventricle; RV = right ventricle